CorMedix Inc. to Host Regulatory Update Conference Call

Rhea-AI Summary

CorMedix Inc. (NASDAQ: CRMD) announced a conference call on March 9, 2021, at 8:30 am ET, to discuss a regulatory update for DefenCath™. This biopharmaceutical company is focused on developing therapies to prevent and treat infectious diseases, with DefenCath designed to prevent bloodstream infections related to central venous catheters in chronic hemodialysis patients. The FDA has granted DefenCath Fast Track designation and Qualified Infectious Disease Product status, extending its marketing exclusivity.

BERKELEY HEIGHTS, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will host a conference call relating to a regulatory update for DefenCath™ at 8:30am ET on March 9, 2021.

Tuesday, March 9th @ 8:30am ET
Domestic:	877-423-9813
International:	201-689-8573
Conference ID:	13717520
Webcast:	Webcast Link

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels.  The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.  Neutrolin^® is CE Marked and marketed in Europe and other territories as a medical device.  For more information, visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
(617) 430-7576

FAQ

What is the date and time of the CorMedix conference call?

The CorMedix conference call is scheduled for March 9, 2021, at 8:30 am ET.

What is the purpose of the conference call hosted by CorMedix?

The conference call will provide a regulatory update on the product DefenCath™.

What is DefenCath™ developed by CorMedix?

DefenCath™ is an antibacterial and antifungal solution designed to prevent bloodstream infections in patients using central venous catheters.

What designations has DefenCath™ received from the FDA?

DefenCath™ has been designated as a Fast Track product and a Qualified Infectious Disease Product by the FDA.

How can I access the conference call for CorMedix?

You can access the conference call by dialing 877-423-9813 (domestic) or 201-689-8573 (international) using the Conference ID 13717520, or by visiting the webcast link.